tiprankstipranks
Electromed (ELMD)
XASE:ELMD
US Market
Want to see ELMD full AI Analyst Report?

Electromed (ELMD) Earnings Dates, Call Summary & Reports

267 Followers

Earnings Data

Report Date
Sep 01, 2026
After Close (Confirmed)
Period Ending
2026 (Q4)
Consensus EPS Forecast
0.32
Last Year’s EPS
0.25
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings

Earnings Call Summary

Q3 2026
Earnings Call Date:May 12, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call highlights strong, broad-based financial performance (double-digit revenue growth, high operating leverage, margin durability), improved operational capability (completed manufacturing optimization, ePrescribe adoption), a healthy balance sheet (cash, no debt) and a large addressable bronchiectasis market supported by active clinical and digital outreach. Challenges include modest non-core revenue, reliance on ramping sales rep headcount for incremental growth, slowed share repurchases due to macro uncertainty, and remaining uncertainty on guideline publication and conversion rates from clinician engagement. Overall, the positives (robust revenue and profit expansion, operational wins, market opportunity) substantially outweigh the negatives.
Company Guidance
Management guided that Electromed expects to continue delivering double‑digit revenue growth with expanded operating leverage as it closes fiscal 2026, touting plans to grow field coverage (ending Q3 with 58 reps, now 62 territories and targeting 4–5 additional reps next fiscal year with a typical 4–6 month ramp), and to scale ePrescribe adoption (40% of orders in Q3, driving a 5‑day average reduction in days‑to‑ship and positioning the company ahead of CMS’s May 2028 fax phase‑out). They reiterated capital return optionality under a Board‑approved $10.0M repurchase authorization ( $3.9M repurchased YTD, activity slowed in Q3), while citing Q3 operating momentum—net revenues $18.6M (+18.4%), home care $16.7M (+18.6%), hospital $1.0M (+42.5%), gross profit $14.6M (78.8% margin), operating income $3.8M (20.3% of revenue, +76%), net income $3.0M ($0.35 diluted)—and a strong balance sheet ($17.0M cash, $28.3M AR, no debt, $40.0M working capital, $49.2M shareholders’ equity). They emphasized commercial levers (86% covered lives, digital campaign with >2.0M impressions and ~65,000 landing‑page visits, 4 regional and 3 national conferences plus 4 webinars with ~375 clinicians) and clinical opportunity (≈923,000 diagnosed U.S. bronchiectasis patients with only 16% on HFCWO and a registry finding 58% of qualifying patients not prescribed HFCWO) as the rationale for continued investment and growth.
Consistent Top-Line and Profit Growth
Revenue of $18.6M, up 18.4% year-over-year; 14th consecutive quarter of year-over-year revenue and profit growth. Net income $3.0M, up 58.8%, and diluted EPS $0.35, up 67% versus prior year.
Strong Operating Leverage and Margins
Operating income increased to $3.8M, a 76% increase year-over-year, representing 20.3% of net revenues. Gross profit rose to $14.6M and gross margin expanded to 78.8% from 78.0% (≈ +0.8 percentage points).
Robust Home Care Performance
Direct Home Care revenue of $16.7M (up ~18.6% YoY). Annualized home care revenue per weighted average direct sales representative was $1.168M, exceeding target range of $1.0M–$1.1M.
High Growth in Hospital Channel
Hospital revenue grew 42.5% year-over-year to $1.0M, rebounding after a slower prior quarter and showing diversification across channels.
Solid Balance Sheet and Cash Generation
Cash balance of $17.0M, no debt, working capital of $40M and shareholders' equity of $49.2M. Positive operating cash flow of $6.7M for the nine months ended March 31, 2026; cash increased $1.7M over the prior-year nine-month period.
Commercial and Operational Execution (ePrescribe & Manufacturing)
Smart Order ePrescribe processed over 40% of orders in Q3 and delivered a 5-day reduction in average days-to-ship versus fax orders. Manufacturing optimization plan completed; products assembled in the U.S.; 99% of net revenues generated in the U.S.
Large Addressable Market and Effective Awareness Programs
Company highlighted ~923,000 diagnosed bronchiectasis patients in the U.S. with only 16% receiving HFCWO therapy (large upside). Digital campaign: >2M impressions and >65,000 visits to educational pages. Clinical outreach included 4 regional conferences, 3 national conferences and 4 webinars attended by ~375 clinicians; manuscript showed 58% of qualifying patients not prescribed HFCWO, underscoring market opportunity.

Electromed (ELMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ELMD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Sep 01, 2026
2026 (Q4)
0.32 / -
0.25
May 12, 2026
2026 (Q3)
0.25 / 0.35
0.2166.67% (+0.14)
Feb 10, 2026
2026 (Q2)
0.26 / 0.32
0.2245.45% (+0.10)
Nov 12, 2025
2026 (Q1)
0.20 / 0.25
0.1656.25% (+0.09)
Aug 26, 2025
2025 (Q4)
0.22 / 0.25
0.225.00% (+0.05)
May 13, 2025
2025 (Q3)
0.20 / 0.21
0.1723.53% (+0.04)
Feb 11, 2025
2025 (Q2)
0.18 / 0.22
0.1915.79% (+0.03)
Nov 12, 2024
2025 (Q1)
0.03 / 0.16
0.02700.00% (+0.14)
Aug 27, 2024
2024 (Q4)
0.14 / 0.20
0.1266.67% (+0.08)
May 07, 2024
2024 (Q3)
0.13 / 0.17
0.1241.67% (+0.05)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ELMD Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 12, 2026
$27.20$34.03+25.11%
Feb 10, 2026
$28.06$25.26-9.98%
Nov 12, 2025
$25.38$26.35+3.82%
Aug 26, 2025
$20.66$24.77+19.89%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Electromed (ELMD) report earnings?
Electromed (ELMD) is schdueled to report earning on Sep 01, 2026, After Close (Confirmed).
    What is Electromed (ELMD) earnings time?
    Electromed (ELMD) earnings time is at Sep 01, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ELMD EPS forecast?
          ELMD EPS forecast for the fiscal quarter 2026 (Q4) is 0.32.